Dennis L Cooper

Dr. Dennis L Cooper

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
MGMendel Goldfinger
Mendel Goldfinger
DCDennis L Cooper
Dennis L Cooper

8 March 2021 in Blood Advances
Verified
Journal Article
Open access
PDF file
ABAndrew R. Branagan
Andrew R. Branagan
EDEamon Duffy
Eamon Duffy
GGGeliang Gan
Geliang Gan
FLFangyong Li
Fangyong Li
CFConnor Foster
Connor Foster
MDMadhav V. Dhodapkar
Madhav V. Dhodapkar
Patients with plasma cell dyscrasias (PCDs) experience an increased burden of influenza, and current practice of single-dose annual influenza vaccination yields suboptimal protective immunity in these patients. Strategies to improve immunity to influenza in these patients are clearly needed. We performed a randomized, double-blind, placebo-controlled clinical trial comparing tandem Fluzone High-Dose influenza vaccination with standard-of-care influenza vaccination. Standard-of-care vaccination was single-dose age-based vaccination (standard dose, <65 years; high dose, ≥65 years), and patients in this arm received a saline placebo injection at 30 days. A total of 122 PCD patients were enrolled; 47 received single-dose standard-of-care vaccination, and 75 received 2 doses of Fluzone High-Dose vaccine. Rates of hemagglutinin inhibition (HAI) titer seroprotection against all 3 strains (H1N1, H3N2, and influenza B) were significantly higher for patients after tandem high-dose vaccination vs control (87.3% vs 63.2%; P = .003) and led to higher seroprotection at the end of flu season (60.0% vs 31.6%; P = .04). These data demonstrate that tandem high-dose influenza vaccination separated by 30 days leads to higher serologic HAI titer responses and more durable influenza-specific immunity in PCD patients. Similar vaccine strategies may also be essential to achieve protective immunity against other emerging pathogens such as novel coronavirus in these patients. This trial was registered at www.clinicaltrials.gov as #NCT02566265.

21 June 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
DLDavid Levitz
David Levitz
YSYogen Saunthararajah
Yogen Saunthararajah
KFKateryna Fedorov
Kateryna Fedorov
LSLauren C. Shapiro
Lauren C. Shapiro
IMIoannis Mantzaris
Ioannis Mantzaris
MGMendel Goldfinger
Mendel Goldfinger
Purpose: Venetoclax (VEN) added to the hypomethylating agents (HMA) decitabine or azacitidine is the new standard of care for elderly patients with acute myeloid leukemia (AML) and is being evaluated in myelodysplastic syndrome (MDS). Current dosing of HMA/VEN relies on leukemia suppression through cytotoxicity which also impacts normal hematopoiesis. A regimen using once-weekly low-dose decitabine (LDDec) has demonstrated activity in myeloid malignancies. To overcome the severe myelosuppression often seen with HMA/VEN, we evaluated a once-weekly dosing regimen of VEN and LDDec in elderly and/or frail patients who were felt less likely to tolerate severe myelosuppression. Patients and Methods: This is a retrospective, single-center analysis of patients with AML, MDS, or chronic myelomonocytic leukemia treated with a once-weekly LDDec/VEN regimen. We also compare this regimen with a cohort treated with standard dosing HMA/VEN. Results: In a retrospective cohort of 39 patients, the overall response rate for patients receiving LDDec/VEN for first-line AML and MDS was 88% and 64%, respectively. In patients with TP53 mutations, the composite complete response rate was 71% and the median overall survival was 10.7 months. When compared with 36 patients receiving standard dose HMA/VEN, the LDDec/VEN patients had a longer time on therapy (175 vs. 78 days; P = 0.014) and a trend toward a higher rate of transfusion independence (47% vs. 26%; P = 0.33). Neutropenic fever occurred in 31% of patients, with a median of one hospitalization at any point during treatment. Conclusions: This preliminary clinical experience, although retrospective, provides proof-of-activity of noncytotoxic DNA methyltransferase 1–targeting by allowing frequent, sustained drug exposure often not possible with standard HMA/VEN regimens.

1 December 2020 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
DCDennis L Cooper
Dennis L Cooper
JMJacqueline Manago
Jacqueline Manago
VPVimal Patel
Vimal Patel
DSDale Schaar
Dale Schaar
TKTracy Krimmel
Tracy Krimmel
RSRoger Strair
Roger Strair

1 January 2006 in Seminars in Nuclear Medicine
Verified
Journal Article
Closed access
PKPhillip H. Kuo
Phillip H. Kuo
DCDennis L Cooper
Dennis L Cooper
DCDavid W. Cheng
David W. Cheng

11 November 2021 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
MSMansi R. Shah
Mansi R. Shah
AGAlissa Gabel
Alissa Gabel
SBStephanie Beers
Stephanie Beers
GSGratian Salaru
Gratian Salaru
YLYong Lin
Yong Lin
DCDennis L Cooper
Dennis L Cooper